公开(公告)号：US09932317B2

公开(公告)日：2018-04-03

申请号：US14385268

申请日：2013-03-19

申请人： Imperial Innovations Limited ,  Emory University

发明人： Robert Brown ,  Matthew John Fuchter ,  Nadine Chapman-Rothe ,  Nitipol Srimongkolpithak ,  Joachim Caron ,  James Snyder ,  Thota Ganesh ,  Jin Liu ,  Aiming Sun

IPC分类号： C07D401/12 ,  C07D401/14 ,  A61K31/517 ,  C07D239/95 ,  C07D405/14 ,  C07D491/056 ,  C07D403/12 ,  C07D401/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551

CPC分类号： C07D239/95 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D491/056

摘要： This invention relates to quinazoline compounds of Formula (I) which are inhibitors of the histone lysine methyltransferase (HKMTase) EZH2, and to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of EZH2 provides a therapeutic or prophylactic effect.

公开(公告)号：US20190202826A1

公开(公告)日：2019-07-04

申请号：US16301421

申请日：2017-05-11

申请人： Emory University

发明人： Qi Shi ,  Thomas Kaiser ,  John DiRaddo ,  James Snyder ,  Dennis Liotta ,  Zackery Dentmon

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.

公开(公告)号：US10947225B2

公开(公告)日：2021-03-16

申请号：US16301421

申请日：2017-05-11

申请人： Emory University

发明人： Qi Shi ,  Thomas Kaiser ,  John DiRaddo ,  James Snyder ,  Dennis Liotta ,  Zackery Dentmon

IPC分类号： C07D471/04 ,  A61K31/4745

摘要： This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.